Using advanced gene editing to eliminate hepatitis B virus DNA
Chemically ligated-guide RNA (lgRNA)-based CRISPR/Cas9 gene editing for elimination of hepatitis B virus cccDNA
This study is exploring a new way to use gene editing to remove the hepatitis B virus from the liver, which could help people with chronic hepatitis B find a potential cure.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baruch S. Blumberg Institute NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project ID | NIH-11002268 on NIH RePORTER |
What this research studies
This research focuses on developing a new gene editing technology that targets and eliminates the DNA of the hepatitis B virus (HBV) from infected liver cells. By utilizing a chemically ligated guide RNA (lgRNA) combined with CRISPR/Cas9, the researchers aim to improve the efficiency and effectiveness of the treatment. The approach involves optimizing the guide RNA to enhance its ability to edit the viral DNA, potentially leading to a cure for chronic hepatitis B. Patients with chronic HBV infection may benefit from this innovative treatment if it proves successful.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic hepatitis B infection.
Not a fit: Patients who do not have chronic hepatitis B or those with acute hepatitis B may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking cure for chronic hepatitis B, significantly improving the quality of life for affected patients.
How similar studies have performed: Previous studies have shown promise in using CRISPR technology for gene editing in similar contexts, indicating potential for success in this novel application.
Where this research is happening
Doylestown, United States
- Baruch S. Blumberg Institute — Doylestown, United States (Active)
Researchers
- Principal investigator: Guo, Ju-Tao — Baruch S. Blumberg Institute
- Study coordinator: Guo, Ju-Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.